Schizophrenia

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

The HHS secretary overstated preliminary research showing the benefits of a keto diet in patients with schizophrenia who remain adherent to medications.

In addition to increased prevalence, the age of diagnosis has also decreased.

Explore how pharmacist-led long-acting injectables (LAIs) enhance medical adherence for schizophrenia patients, improving care transitions and outcomes.

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

Research shows that individuals who use cannabis to self-medicate, especially those with a history of childhood trauma, face heightened risks of paranoia and adverse mental health outcomes.

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

A multidisciplinary team enhances psychiatric care by empowering community pharmacists to administer long-acting injectable antipsychotics, improving patient adherence and outcomes.

New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

Schizophrenia is a chronic mental illness that significantly affects patients through its symptoms, associated health conditions, and treatment challenges, with long-acting injectable antipsychotics offering potential benefits in improving adherence and reducing relapses.

The move is expected to expand clozapine access for patients with schizophrenia.

In the phase 3 CONNEX clinical trial program, iclepertin did not meet its primary and secondary end points.

The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain.

In the trial, lumateperone had a significantly longer time to relapse in patients treated compared to placebo.

Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

Paliperidone palmitate (Erzofi; Luye Pharma Group) is approved as a monotherapy for schizophrenia and as an adjunct for schizoaffective disorder.

Vitamin D deficiency (VDD) is an important factor in the pathogens of schizophrenia.

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia